Gyre Therapeutics (NASDAQ:GYRE) Trading Up 7.9% – Should You Buy?

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) were up 7.9% during mid-day trading on Thursday . The company traded as high as $6.04 and last traded at $6.14. Approximately 24,311 shares were traded during trading, a decline of 73% from the average daily volume of 90,412 shares. The stock had previously closed at $5.69.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Weiss Ratings cut shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Zacks Research cut shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Finally, Wall Street Zen cut shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Gyre Therapeutics has an average rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Price Performance

The company’s 50 day moving average is $7.01 and its two-hundred day moving average is $7.49. The firm has a market cap of $600.13 million, a P/E ratio of -68.54 and a beta of 1.90.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. Research analysts predict that Gyre Therapeutics, Inc. will post -0.3 EPS for the current year.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, CEO Ying Luo sold 10,136 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the transaction, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. This trade represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $6.15, for a total transaction of $78,843.00. Following the transaction, the chief operating officer owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. This represents a 1.80% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 32,535 shares of company stock valued at $219,580. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in Gyre Therapeutics by 72.5% during the fourth quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock worth $220,000 after purchasing an additional 13,074 shares during the period. Alliancebernstein L.P. lifted its stake in Gyre Therapeutics by 9.5% during the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock worth $163,000 after purchasing an additional 1,900 shares during the period. Barclays PLC lifted its stake in Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after purchasing an additional 5,135 shares during the period. Lazard Asset Management LLC bought a new position in Gyre Therapeutics during the third quarter worth about $111,000. Finally, Wells Fargo & Company MN raised its stake in shares of Gyre Therapeutics by 132.4% in the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after acquiring an additional 7,361 shares during the last quarter. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.